Talk:Sitaxentan

spelling of sitaxentan
This article begins with a mention regarding the spelling of sitaxentan. In essence, it says sitaxsentan is incorrectly spelled.

According to the Monograph (from Pfizer) posted on the electronic Compendium of pharmaceuticals and Specialties (CPS, published by the Canadian Pharmacists Association), the spelling sitaxsentan is fine.

This is what Canadians will read when prescribed this drug. Actually, typing sitaxentan in the eCPS query field yields no result.

Moreover, a quick search on Google yielded 20400 results fort sitaxsentan and 25600 for sitaxentan. Both terms seem accepted.

My suggestion is to remove the wording incorrectly from the assertion.

Myrgag (talk) 19:34, 3 March 2010 (UTC)


 * With active ingredients the WHO's List of Recommended International Non-proprietary Names (INN) should be regarded as the sole authority. In list No. 45 (published in WHO Drug Information, Vol. 15, No. 1, 2001, online at http://whqlibdoc.who.int/druginfo/INN_2001_list45.pdf) it specifies on p. 51 "sitaxentanum / sitaxentan" - clearly making "sitaxsentan" the misspelled version. The s probably slipped in because the other drugs of this class (bosentan, ambrisentan,...) happen to have an s at this place, and so the notion arose that these are the "-sentan" drugs (just as the AT-II antagonists are the "-sartan" class). But the API's INN is very clearly specified without an s by the WHO, and so "sitaxentan" should stand. Glst2 (talk) 18:48, 4 March 2010 (UTC)